A longitudinal study of JC virus serostatus stability among multiple sclerosis patients
Affiliations
Affiliations
- Division of Neurology, Amiri Hospital, Arabian Gulf Street, Sharq 13041, Kuwait; Neurology Clinic, Dasman Diabetes Institute, P.O. Box 1180, Dasman 15462, Kuwait. Electronic address: alroughani@gmail.com.
- Department of Community Medicine & Behavioural Sciences, Faculty of Medicine, University of Kuwait, PO Box 24923, Safat 13110, Kuwait.
- Department of Neurology, Ibn Sina Hospital, P.O. Box 25427, Safat 13115, Kuwait; Department of Neurology and Psychiatry, Minia University, P.O. Box 61519, Minia 61111, Egypt.
- Department of Neurology, Ibn Sina Hospital, P.O. Box 25427, Safat 13115, Kuwait; Department of Medicine, Faculty of Medicine, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait.
Abstract
Background: Anti-JC virus (JCV) antibody testing has been used increasingly to stratify multiple sclerosis (MS) patients into different disease modifying therapies.
Objectives: We assessed JCV serostatus stability longitudinally in MS patients who were regularly tested for anti-JCV antibody and examined the demographic and clinical factors associated with JCV serostatus.
Methods: The data of MS patients who were screened for anti-JCV antibody using the two-step second-generation ELISA were collected between 1st October 2014 and 31st October 2015 at the MS clinic, Kuwait. Demographics, disease characteristics and JCV serostatus, including antibody index (AI), were obtained for patients with at least 12-months of follow-up results. Stable JCV serostatus was defined as anti-JCV antibody status that remained consistently negative or positive throughout the observation period. A change in serostatus was confirmed by a follow-up test at 6 months. Patients were labeled as JCV seroconverters (negative to positive), JCV seroreverters (positive to negative) or intermittently seropositive.
Results: This study included 168 MS patients with anti-JCV antibody results for at least 1 year. Mean age and mean disease duration were 33.4 ± 9.8 and 8.1 ± 5.6 years respectively. In this cohort, 94% (n = 158) patients received natalizumab treatment with a mean of 27.2 ± 13.8 infusions. JCV stable serostatus (positive or negative) was observed in 84.5% (n = 142) with a mean follow-up duration of 23.8 ± 7.0 months. In this longitudinal study, relatively high frequencies of seroconverters (11.5%), intermittently seropositive (9.7%) and seroreverters (3.6%) were recorded. Age, gender, disease duration and number of natalizumab infusions did not influence JCV serostatus stability. JCV seroconversion risk was low with persistent AI < 0.9 beyond 18 months of initial testing.
Conclusion: Anti-JCV antibody index at baseline predicted stable negative as well as stable positive JCV serostatus over the observational period. The AI < 0.9 appeared to have a significant implication in the longitudinal stability of JCV AI in patients who were intermittently seropositive.
Keywords: Antibody index; JC virus; Kuwait; Multiple sclerosis; Risk stratification.
Similar articles
Hegen H, Auer M, Bsteh G, Di Pauli F, Plavina T, Walde J, Deisenhammer F, Berger T.PLoS One. 2017 Mar 20;12(3):e0174005. doi: 10.1371/journal.pone.0174005. eCollection 2017.PMID: 28319193 Free PMC article.
Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
Trampe AK, Hemmelmann C, Stroet A, Haghikia A, Hellwig K, Wiendl H, Goelz S, Ziegler A, Gold R, Chan A.Neurology. 2012 May 29;78(22):1736-42. doi: 10.1212/WNL.0b013e3182583022. Epub 2012 May 16.PMID: 22592369
Conversion and reversion of anti-John Cunningham virus antibody serostatus: A prospective study.
Auer M, Hegen H, Sellner J, Oppermann K, Bsteh G, Di Pauli F, Berger T, Deisenhammer F.Brain Behav. 2019 Jul;9(7):e01332. doi: 10.1002/brb3.1332. Epub 2019 Jun 6.PMID: 31168964 Free PMC article.
Schwab N, Schneider-Hohendorf T, Hoyt T, Gross CC, Meuth SG, Klotz L, Foley JF, Wiendl H.Mult Scler. 2018 Apr;24(5):563-573. doi: 10.1177/1352458517728814. Epub 2017 Aug 29.PMID: 28847222 Review.
Paz SPC, Branco L, Pereira MAC, Spessotto C, Fragoso YD.Epidemiol Health. 2018 Jan 5;40:e2018001. doi: 10.4178/epih.e2018001. eCollection 2018.PMID: 29370683 Free PMC article. Review.